|
1
|
Goldhirsch A, Ingle JN, Gelber RD, Coates
AS, Thürlimann B and Senn HJ; Panel members. Thresholds for
therapies: highlights of the St Gallen International Expert
Consensus on the primary therapy of early breast cancer 2009. Ann
Oncol. 20:1319–1329. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hortobagyi GN: Treatment of breast cancer.
N Engl J Med. 339:974–984. 1998. View Article : Google Scholar
|
|
3
|
Colozza M, Azambuja E, Cardoso F, Sotiriou
C, Larsimont D and Piccart MJ: Proliferative markers as prognostic
and predictive tools in early breast cancer: where are we now? Ann
Oncol. 16:1723–1739. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stuart-Harris R, Caldas C, Pinder SE and
Pharoah P: Proliferation markers and survival in early breast
cancer: a systematic review and meta-analysis of 85 studies in
32,825 patients. Breast. 17:323–334. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar
|
|
6
|
Harris L, Fritsche H, Mennel R, et al:
American Society of Clinical Oncology 2007 update of
recommendations for the use of tumor markers in breast cancer. J
Clin Oncol. 25:5287–5312. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Polley MY, Leung SC, McShane LM, Gao D,
Hugh JC, Mastropasqua MG, Viale G, Zabaglo LA, Penault-Llorca F,
Bartlett JM, Gown AM, Symmans WF, Piper T, Mehl E, Enos RA, Hayes
DF, Dowsett M and Nielsen TO; International Ki67 in Breast Cancer
Working Group of the Breast International Group and North American
Breast Cancer Group. An international Ki67 reproducibility study. J
Natl Cancer Inst. 105:1897–1906. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nishimura R, Osako T, Okumura Y, Hayashi
M, Toyozumi Y and Arima N: Ki-67 as a prognostic marker according
to breast cancer subtype and a predictor of recurrence time in
primary breast cancer. Exp Ther Med. 1:747–754. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
de Azambuja E, Cardoso F, de Castro G Jr,
et al: Ki-67 as prognostic marker in early breast cancer: a
meta-analysis of published studies involving 12155 patients. Br J
Cancer. 96:1504–1513. 2007.PubMed/NCBI
|
|
10
|
Jonat W and Arnold N: Is the Ki-67
labelling index ready for clinical use? Ann Oncol. 22:500–502.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yerushalmi R, Woods R, Ravdin PM, Hayes MM
and Gelmon KA: Ki67 in breast cancer: prognostic and predictive
potential. Lancet Oncol. 11:174–183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Delpech Y, Wu Y, Hess KR, Hsu L, Ayers M,
Natowicz R, Coutant C, Rouzier R, Barranger E, Hortobagyi GN, Mauro
D and Pusztai L: Ki67 expression in the primary tumor predicts for
clinical benefit and time to progression on first-line endocrine
therapy in estrogen receptor-positive metastatic breast cancer.
Breast Cancer Res Treat. 135:619–627. 2012. View Article : Google Scholar
|
|
13
|
Kai K, Nishimura R, Arima N, Miyayama H
and Iwase H: p53 expression status is a significant molecular
marker in predicting the time to endocrine therapy failure in
recurrent breast cancer: a cohort study. Int J Clin Oncol.
11:426–433. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Goldhirsch A, Glick JH, Gelber RD and Senn
HJ: Meeting highlights: International Consensus Panel on the
Treatment of Primary Breast Cancer. J Natl Cancer Inst.
90:1601–1608. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Taktak AF, Eleuteri A, Lake SP and Fisher
AC: A web-based tool for the assessment of discrimination and
calibration properties of prognostic models. Comput Biol Med.
38:785–791. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Harrell FE Jr, Califf RM, Pryor DB, et al:
Evaluating the yield of medical tests. JAMA. 247:2543–2546. 1982.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dowsett M, Nielsen TO, A’Hern R, Bartlett
J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T,
McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J,
Sotiriou C, Smith IE, Viale G, Zujewski JA and Hayes DF;
International Ki-67 in Breast Cancer Working Group. Assessment of
Ki67 in breast cancer: recommendations from the International Ki67
in Breast Cancer Working Group. J Natl Cancer Inst. 103:1656–1664.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Reyal F, Hajage D, Savignoni A, et al:
Long-term prognostic performance of Ki67 rate in early stage,
pT1-pT2, pN0, invasive breast carcinoma. PLoS One. 8:e559012013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Honma N, Horii R, Iwase T, Saji S, Younes
M, Ito Y and Akiyama F: Ki-67 evaluation at the hottest spot
predicts clinical outcome of patients with hormone
receptor-positive/HER2-negative breast cancer treated with adjuvant
tamoxifen monotherapy. Breast Cancer. Mar 12–2013.(Epub ahead of
print).
|
|
20
|
Nishimura R, Osako T, Okumura Y, Tashima
R, Toyozumi Y and Arima N: Changes in the ER, PgR, HER2, p53 and
Ki-67 biological markers between primary and recurrent breast
cancer: discordance rates and prognosis. World J Surg Oncol.
9:131–137. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nishimura R, Osako T, Nishiyama Y, Tashima
R, Nakano M, Fujisue M, Toyozumi Y and Arima N: Evaluation of
factors related to late recurrence - later than 10 years after the
initial treatment - in primary breast cancer. Oncology. 85:100–110.
2013.
|
|
22
|
Pathmanathan N, Balleine RL, Jayasinghe
UW, Bilinski KL, Provan PJ, Byth K, Bilous AM, Salisbury EL and
Boyages J: The prognostic value of Ki67 in systemically untreated
patients with node-negative breast cancer. J Clin Pathol.
67:222–228. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ribelles N, Perez-Villa L, Jerez JM,
Pajares B, Vicioso L, Jimenez B, de Luque V, Franco L, Gallego E,
Marquez A, Alvarez M, Sanchez-Muñoz A, Perez-Rivas L and Alba E:
Pattern of recurrence of early breast cancer is different according
to intrinsic subtype and proliferation index. Breast Cancer Res.
15:R982013. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ibrahim T, Farolfi A, Scarpi E, Mercatali
L, Medri L, Ricci M, Nanni O, Serra L and Amadori D: Hormonal
receptor, human epidermal growth factor receptor-2, and Ki67
discordance between primary breast cancer and paired metastases:
clinical impact. Oncology. 84:150–157. 2013. View Article : Google Scholar
|
